Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AT-752 · 1 trial · 1 indication
Maximum plasma concentration (Cmax)
Maximum plasma concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| AT-752 250 mg single dose | EXPERIMENTAL | AT-752 administered orally, 250 mg on Day 1 |
| Placebo -single dose | PLACEBO_COMPARATOR | Matching placebo administered orally on Day 1 |
| AT-752 500 mg single dose | EXPERIMENTAL | AT-752 administered orally, 500 mg single doses on Day 1 and Day 7 |
| Placebo- single dose | PLACEBO_COMPARATOR | Matching placebo administered orally on Day 1 and Day 7 |
| AT-752 1000 mg single dose | EXPERIMENTAL | AT-752 administered orally, 1000 mg single dose on Day 1 |
| Placebo - single dose | PLACEBO_COMPARATOR | Matching placebo administered orally on Day 1 |
| AT-752 1500 mg single dose | EXPERIMENTAL | AT-752 administered orally, 1500 mg single dose on Day 1 |
| Placebo: single dose | PLACEBO_COMPARATOR | Matching placebo administered orally on Day 1 |
| AT-752 - 1000 mg QD multiple doses | EXPERIMENTAL | AT-752 - administered orally, 1000 mg once daily (QD) for 7 days |
| Placebo - Administered once daily (QD) | PLACEBO_COMPARATOR | Matching placebo administered orally once daily (QD) for 7 days |
| AT-752 - 750 mg twice daily (BID) | EXPERIMENTAL | AT-752 administered orally, 750 mg twice daily (BID) for 4 days plus one dose on Day 5. |
| Placebo - Administered twice daily (BID) | PLACEBO_COMPARATOR | Matching placebo administered orally twice daily (BID) for 4 days plus one dose on Day 5. |
| AT-752 - 750 mg three times daily (TID) | EXPERIMENTAL | AT-752 administered orally, 750 mg three times daily (TID) for 4 days plus one dose on Day 5. |
| Placebo - Administered TID | PLACEBO_COMPARATOR | Matching placebo administered orally (TID) for 4 days plus one dose on Day 5. |
| Name | Type | Description |
|---|---|---|
| AT-752 | DRUG | Parallel Assignment |
| Placebo | DRUG | Parallel Assignment |
Inclusion Criteria: 1. Body mass index (BMI) of 18-29 kg/m2 2. Must agree to use protocol-specified methods of contraception 3. Negative pregnancy test 4. Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: 1. Pregnant or breastfeeding 2. Abus...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Qdenga |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
AT-752 is an investigational small molecule antiviral being developed by Atea Pharmaceuticals, Inc. for the treatment of dengue. It is in Phase 1 clinical development and has been studied in healthy adult volunteers. AT-752 has not been approved by the FDA and remains an investigational agent.
AT-752 is being developed for the treatment of dengue, a mosquito-borne viral infection. Its clinical testing to date has been in healthy volunteers rather than in patients with dengue. Atea Pharmaceuticals is the developer. The drug remains investigational and is not approved for any use.
AT-752 targets HCV NS5A, a viral nonstructural protein. NS5A is a protein target, and AT-752 is a small molecule antiviral. The compound is being developed by Atea Pharmaceuticals for dengue, an infectious disease indication.
AT-752 is being developed by Atea Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker AVIR. Atea is the sponsor of the clinical program for AT-752 in dengue.
AT-752 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program has completed one trial, and no trials are currently active.
AT-752 has been studied in one completed Phase 1 trial, NCT04722627, titled Study of AT-752 in Healthy Subjects. The trial enrolled 65 participants in Australia, was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.